New drug cocktail aims to outsmart relapsed leukemia
NCT ID NCT03874052
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing whether adding ruxolitinib to the standard drugs azacitidine and venetoclax is safe for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. About 51 adults will receive the three-drug combination to find the best dose and check for side effects. The goal is to see if this approach can help control the disease better than current options.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ruxolitinib, azacitidine, and venetoclax
What this could lead to
If it works, this could offer a new treatment option for patients with AML that has returned or not responded to prior therapy.
What could go wrong
This is a very early Phase 1 trial with only 51 participants, so the main goal is safety, not proof of effectiveness. The combination may cause significant side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OHSU Knight Cancer Institute
RECRUITINGPortland, Oregon, 97239, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Ohio State University Comprehensive Cancer Center
SUSPENDEDColumbus, Ohio, 43210, United States
-
UT Southwestern/Simmons Cancer Center-Dallas
SUSPENDEDDallas, Texas, 75390, United States